EYPT241220P7500
- 0.15
- 0.000.00%
EyePoint Pharmaceuticals Newsroom
Selling EyePoint Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Express News | EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Wall Street Analysts See a 175.07% Upside in EyePoint Pharmaceuticals (EYPT): Can the Stock Really Move This High?
Baird Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $33
JonesTrading Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $45
H.C. Wainwright Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $22
EyePoint Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
EyePoint Pharmaceuticals Price Target Cut to $22.00/Share From $30.00 by HC Wainwright & Co.
Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Raises Price Target to $33
EyePoint Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
TD Cowen Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $20
EyePoint Pharmaceuticals: Advancements in Clinical Trials and Promising Interim Data Boost Buy Rating
EyePoint Pharmaceuticals: Q3 Earnings Snapshot
Express News | EyePoint Pharmaceuticals Inc: $161.0 Mln Oversubscribed Equity Financing Extends Cash Runway Into 2027
Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q3 Revenue $10.5M
EyePoint Pharmaceuticals | 8-K: EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
Express News | EyePoint Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Corporate Developments
Express News | EyePoint Pharmaceuticals Q3 Net Income USD -29.361 Million
EyePoint Pharmaceuticals 3Q Loss/Shr 54c >EYPT
With 61% Ownership, EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Boasts of Strong Institutional Backing